Title: Neuroinflammatory Pathways as Treatment Targets and Biomarker Candidates in Drug-Resistant Epilepsy
Date: Friday, October 2, 2026
Time: 9:00 AM EST
Annamaria Vezzani, PhD in Neuropharmacology, head of the Laboratory of Experimental Epilepsy and Therapeutic strategies, Department of Acute Brain Injury at the Mario Negri Institute for Pharmacological Research in Milano. Post-docs at the Karolinska Institute, Stockholm and the University of Maryland, Baltimore, USA and on sabbatical at the Albert Einstein Medical School, Bronx N.Y.
Main research focus is on molecular mechanisms involved in the pathogenesis of seizures and epileptogenesis in acquired epilepsies, with special interest in developing new treatments and biomarkers. Author of over 200 original papers, several book chapters and reviews in peer-reviewed high impact scientific journals (h-index108).
Associate Editor of Basic Science for Epilepsy for 8 years. Appointed of the Chair of the Commission on Neurobiology of the International League Against Epilepsy (ILAE, 2005-2009) to promote translational research in epilepsy. Past member of the Commission on European Affairs (2013-2017) of ILAE to promote educational initiatives for clinicians and basic scientists. Member of the Innovative Medicine Initiative (IMI) Scientific Committee (2018-2019). Serving in several editorial boards of scientific journals and American Epilepsy Society and International League Against Epilepsy committees. She received the Research Recognition Award for translational research in 2009 by the American Epilepsy Society.
